Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) saw a downside of -0.43% to close Friday at $16.14 after subtracting -$0.07 on the day. The 5-day average trading volume is 559,280 shares of the company’s common stock. It has gained $17.31 in the past week and touched a new high 2 times within the past 5 days. An average of 492,360 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 453,944.
CRNX’s 1-month performance is -19.30% or -$3.80 on its low of $15.95 reached on 08/17/23. The company’s shares have touched a 52-week low of $15.23 and high of $24.58, with the stock’s rally to the 52-week high happening on 05/10/23. YTD, CRNX has lost -11.80% or -$2.16 and has reached a new high 9 times. However, the current price is down -34.34% from the 52-week high price.
Insider Transactions
CRNX stock investors last saw insider trading activity on Jul 13.Struthers Richard Scott (President & CEO) most recently sold 14,157 shares at $20.35 per share on Jul 13. This transaction cost the insider $288,095. President & CEO, Struthers Richard Scott, sold 11,459 shares at a price of $20.17 on Jul 12. Then, on Jul 11, President & CEO Struthers Richard Scott sold 24,384 shares at a price of $20.14 per share. This transaction amounted to $491,094.
Valuation Metrics
CRNX stock has a beta of 0.87. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 184.70 while the price-to-book (PB) in the most recent quarter is 3.45.
Crinetics Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 8.70, with the current ratio over the same period at 8.70. The trailing 12-month EBITDA margin is -3514.74%. The firm’s gross profit as reported stood at $172.62 million against revenue of $4.74 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 16.87% to -$50.98 million, while revenue of -$46.0 million was 9.77% off the previous quarter. Analysts expected CRNX to announce -$0.86 per share in earnings in its latest quarter, but it posted -$0.94, representing a -9.30% surprise. EBITDA for the quarter stood at more than -$53.63 million. CRNX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 39.14 million, with total debt at $2.56 million. Shareholders hold equity totaling $54.69 million.
Let’s look briefly at Crinetics Pharmaceuticals Inc. (CRNX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 24.01% to suggest the stock is trending oversold, with historical volatility in this time period at 27.78%.
The stock’s 5-day moving average is $16.44, reflecting a -2.27% or -$0.38 change from its current price. CRNX is currently trading -13.74% above its 20-day SMA, +1.32% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -26.97% and SMA200 by-12.57%.
Stochastic %K and %D was 4.53% and 7.79% and the average true range (ATR) pointed at 0.67. The RSI (14) points at 28.95%, while the 14-day stochastic is at 5.26% with the period’s ATR at 0.71. The stock’s 9-day MACD Oscillator is pointing at -0.40 and -1.22 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX), Piper Sandler launched coverage with an Overweight rating. Analysts offering their rating for CRNX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CRNX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 8 have offered a “buy” rating.
What is CRNX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $32.00 and a high of $57.00, with their median price target at $43.00. Looking at these predictions, the average price target given by analysts is for Crinetics Pharmaceuticals Inc. (CRNX) stock is $43.67.
